

Caspofungin (Acetate)

Catalog No: tcsc0578

Available Sizes

Size: 5mg
Size: 10mg
Size: 25mg
Size: 50mg
Size: 100mg
Size: 200mg
Size: 500mg
Size: 1g
Specifications
CAS No: .79463-17-3

Formula:

 $C_{56}H_{96}N_{10}O_{19}$

Pathway:		
Pathway: Anti-infection		
Target		
Target: Fungal		
Purity / Grade:		
Purity / Grade: >98%		
Solubility:		

Copyright 2021 Taiclone Biotech Corp.



H2O : ≥ 100 mg/mL (82.41 mM); DMSO : ≥ 83.3 mg/mL (68.65 mM)

Alternative Names:

L 743872;L 743873;MK 0991


Observed Molecular Weight:

1213.42

Product Description

Caspofungin (Acetate) is an antifungal drug, and noncompetitively inhibits 1,3-β-d glucan synthase activity.

In Vivo: Mice injected with caspofungin at vitreal concentrations from 0.41 to 4.1 μ M do not have significant alterations in their ERG waveforms, and their retinas have no detectable morphologic changes or loss of cells. At the vitreal concentration of 41 μ M, caspofungin reduces the amplitudes of the a-waves, b-waves, and scotopic threshold responses of the ERG and also produces a decrease in the number of cells in the ganglion cell layer^[1]. Caspofungin (8 mg/kg) or amphotericin B at 1 mg/kg given i.p. once daily for 7 days beginning at 30 h after infection resulted in 100% survival through day 28 relative to vehicle control treatment, which results in 100% mortality by day 11 after infectious challenge. Caspofungin reduces recovery of viable Candida from kidney and brain tissues compared to vehicle control treatment on day 5, when control burden peaked. Caspofungin-treated mice dosed with 2 mg/kg or greater have significantly lower brain burden than amphotericin-B-treated mice at day 5. Amphotericin B and caspofungin treatment reduce kidney fungal burden by 1.7 log CFU/g and 2.46 to 3.64 log CFU/g, respectively^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.